ST Germain D J Co. Inc. Increases Stock Position in Stryker Co. (NYSE:SYK)

ST Germain D J Co. Inc. grew its stake in shares of Stryker Co. (NYSE:SYK) by 14.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,362 shares of the medical technology company’s stock after buying an additional 300 shares during the period. ST Germain D J Co. Inc.’s holdings in Stryker were worth $850,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Dunhill Financial LLC lifted its holdings in Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares in the last quarter. Centennial Bank AR lifted its holdings in Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after buying an additional 48 shares in the last quarter. Darwin Wealth Management LLC acquired a new position in Stryker in the 3rd quarter worth $36,000. HBW Advisory Services LLC acquired a new position in Stryker in the 3rd quarter worth $42,000. Finally, Hara Capital LLC acquired a new position in Stryker in the 3rd quarter worth $42,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Trading Up 0.5 %

Stryker stock opened at $366.04 on Friday. The firm has a 50 day simple moving average of $375.40 and a 200-day simple moving average of $357.70. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The stock has a market capitalization of $139.54 billion, a PE ratio of 39.23, a price-to-earnings-growth ratio of 2.82 and a beta of 0.95. Stryker Co. has a 12-month low of $306.10 and a 12-month high of $398.20.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.10. The business had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business’s revenue was up 11.9% on a year-over-year basis. During the same period last year, the firm posted $2.46 earnings per share. As a group, equities research analysts expect that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This is a boost from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. Stryker’s dividend payout ratio (DPR) is 36.01%.

Analysts Set New Price Targets

SYK has been the topic of a number of recent analyst reports. BTIG Research boosted their price objective on shares of Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Evercore ISI upped their target price on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Citigroup upped their target price on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Canaccord Genuity Group upped their target price on shares of Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Finally, UBS Group upped their target price on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $405.80.

Insider Buying and Selling

In related news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 5.50% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.